Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 10, 2021
Becoming a substantial holder
Dec 07, 2021
Positive topline results from Phase 3 trial in Rett syndrome
Nov 10, 2021
Neuren presenting at Bell Potter Healthcare Conference
Oct 28, 2021
Q3 2021 quarterly activity and cash flow report
Oct 21, 2021
Neuren receives feedback on IND for Phelan-McDermid syndrome
Oct 20, 2021
Change of Director's Interest Notice - D Angus
Oct 11, 2021
US patent to 2034 granted for Neuren's NNZ-2591 in autism
Oct 08, 2021
Change of Director's Interest Notice - J Harry
Oct 08, 2021
Change of Director's Interest Notice - J Pilcher
Oct 08, 2021
Change of Director's Interest Notice - P Davies
1
2
3
4
5
6
Next
